Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants

Abstract

AbstractFamitinib is a tyrosine kinase inhibitor under clinical investigation for the treatment of solid tumors. Here, a 3‐period crossover trial investigated the effect of high‐fat or low‐fat food intake on the single‐dose pharmacokinetic properties of oral famitinib. Twenty‐four healthy Chinese participants were enrolled and received a single 25‐mg dose of famitinib malate capsule following a high‐fat or low‐fat breakfast before dosing. Blood samples were collected before dosing (0 hour) to 192 hours after dosing, and famitinib concentrations in plasma were determined with validated liquid chromatography–tandem mass spectrometry. Compared with the fasting condition, the geometric mean ratios for low‐fat/fasting were 98.6%, 107.7%, and 107.5% for maximum plasma concentration, area under the plasma concentration–time curve (AUC) over the dosing interval, and AUC from time 0 to infinity, respectively. Those for high‐fat/fasting were 84.4%, 105.0%, and 105.1% for maximum plasma concentration, AUC over the dosing interval, and AUC from time 0 to infinity, respectively. There was no significant difference in adverse events between fasting and fed conditions, and no serious adverse events occurred during the trial. In conclusion, oral famitinib bioavailability is not affected by food intake, implying that patients with cancer do not need to consider dietary status when using famitinib. This is considered important for convenience and treatment compliance.